| | LRM | FIB-4 | APRI | NFS |
|----------------|---------------|---------------|---------------|-----------------|
| Training Set | | | | |
| AUROC | 0.764 | 0.594 | 0.684 | 0.557 |
| (95%CI) | (0.710-0.816) | (0.503-0.685) | (0.605-0.762) | (0.470 - 0.644) |
| Specificity | 0.801 | 0.799 | 0.600 | 0.387 |
| Sensitivity | 0.751 | 0.321 | 0.698 | 0.743 |
| PPV | 0.664 | 0.447 | 0.291 | 0.233 |
| NPV | 0.903 | 0.850 | 0.794 | 0.858 |
| Validation Set | | | | |
| AUROC | 0.786 | 0.578 | 0.615 | 0.575 |
| (95%CI) | (0.719-0.852) | (0.498-0.659) | (0.532-0.698) | (0.486-0.664) |
| Specificity | 0.815 | 0.321 | 0.801 | 0.791 |
| Sensitivity | 0.726 | 0.870 | 0.389 | 0.389 |
| PPV | 0.711 | 0.239 | 0.339 | 0.313 |
| NPV | 0.854 | 0.825 | 0.804 | 0.841 |

Table 2. Diagnostic performances of LRM, FIB-4, APRI, and NFS scores for identifying the presence of significant fibrosis (defined as fibrosis stage ≥ 2).

Significant liver fibrosis was defined as fibrosis stages 2 or above.

Abbreviations: AUROC, area under the receiver operator characteristic curve; PPV, positive predictive value; NPV, negative predictive value; LRM, logistic regression model; FIB-4, fibrosis-4 index; APRI, AST-to-platelet ratio index; NFS, NAFLD fibrosis score.